Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin

Phase II Study of Nivolumab (Group 1) and Nivolumab Plus Relatlimab (Group 2) in Patients With Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin

To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment (Time Frame Group 2: From first dose up to 5 years)

Study Overview

• Status: Recruiting
• Conditions: Squamous Cell Carcinoma of the Skin
• Intervention / Treatment: Drug: Nivolumab; Drug: Nivolumab plus Relatlimab

• Study Type: Interventional
• Enrollment (Estimated): 61
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Martin Laimer, MD; Phone Number: 58274 +4357255; Email: m.laimer@salk.at
• Study Contact Backup: Name: Roland Lang, PhD; Phone Number: 58200 +4357255; Email: r.lang@sak.at

Study Locations

• Austria
  • Graz, Austria, 8020
    • Recruiting
    • Universitätsklinikum Graz - LKH, Klinische Abteilung für Onkologie
    • Contact: Philipp Jost, MD; Email: philipp.jost@medunigraz.at
  • Innsbruck, Austria, 6020
    • Recruiting
    • LKH Innsbruck Universitätsklinik für Dermatologie und Venerologie
    • Contact: Van Anh Nguyen, MD; Email: van.nguyen@i-med.ac.at
  • Klagenfurt, Austria, 9020
    • Completed
    • Klinikum Klagenfurt am Wörthersee
  • Salzburg, Austria, 5020
    • Recruiting
    • Universitätsklinik für Dermatologie und Allergologie der Paracelsus medizinischen Privatuniversität Salzburg
    • Contact: Martin Laimer, MD; Phone Number: 58274 +4357255; Email: m.laimer@salk.at
    • Contact: Roland Lang, PhD; Phone Number: 58200 +4357255; Email: r.lang@salk.at
  • St.Pölten, Austria, 3100
    • Recruiting
    • Abteilung für Haut- und Geschlechtskrankheiten, Universitätsklinikum St. Pölten Karl Landsteiner Privatuniversität für Gesundheitswissenschaften
    • Contact: Christine Hafner, MD; Email: christine.hafner@edu.kl.ac.at
  • Vienna, Austria, 1090
    • Recruiting
    • Med Uni Wien, Univ. Klinik für Dermatologie
    • Contact: Christoph Höller, MD; Email: christoph.hoeller@meduniwien.ac.at
  • Wels, Austria, 4600
    • Recruiting
    • Klinikum Wels-Grieskirchen GmbH
    • Contact: Matthias Barta, MD; Email: matthias.barta@klinikum-wegr.at

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Men and women, 18 years of age and older on day of signing written informed consent
2. Histologically or cytologically documented locally-advanced and/or metastatic squamous cell carcinoma of the skin (stage III/IV AJCC 2010) that is incurable
3. Archival tumor tissue available for evaluation of PD-L1 and LAG-3 expression
4. Measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
5. Life expectancy of at least 12 weeks
6. Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2

7. Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to registration:

   • WBC ≥ 2000/μl
   • Neutrophils ≥ 1500/μL
   • Platelets ≥ 100 x103/μL
   • Hemoglobin > 9.0 g/dL
   • Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below):

   Female CrCl = (140 - age in years) x weight in kg x 0.85/72 x serum creatinine in mg/dL Male CrCl = (140- age in years) x weight in kg x 1.00/72 x serum creatinine in mg/dL

   • AST/ALT ≤ 3 x ULN
   • Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
   • Negative pregnancy test and effective contraception (Pearl-Index <1) for for women of childbearing potential (WOCBP) if the risk of conception exists
8. Prior radiotherapy must have been completed at least 2 weeks prior to study drug administration
9. Prior systemic antibiotic treatment must have been completed at least 30 days prior to stool sample collection

Exclusion Criteria:

1. Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
2. Prior therapy with CTLA-4, PD-1 or LAG-3 antibodies
3. History of myocarditis, regardless of etiology
4. Troponin T (TnT) or I (TnI) > 2× institutional upper limit of normal (ULN). Participants with TnT or TnI levels between > 1× to 2× ULN will be permitted if repeat levels within 24 hours are ≤ 1× ULN. If TnT or TnI levels are between > 1× to 2× ULN within 24 hours, the participant may undergo a cardiac evaluation and be considered for treatment, based on a favorable benefit/risk assessment by the Investigator. When repeat levels within 24 hours are not available, a repeat test should be conducted as soon as possible. If TnT or TnI repeat levels beyond 24 hours are < 2× ULN, the participant may undergo a cardiac evaluation and be considered for treatment, based on a favorable benefit/risk assessment by the Investigator
5. A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
6. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
7. Known additional malignancy that is progressing or requires active treatment. Patients with chronic lymphocytic leukemia that is stable under active therapy are eligible for inclusion.
8. An active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
9. Patients with serious intercurrent illness, requiring hospitalization
10. Other serious illnesses, e.g. serious infections requiring antibiotics
11. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
12. Pregnancy (absence to be confirmed by ß-HCG urinary test, minimum sensitivity 25 IU/L or equivalent units of HCG)) or lactation period
13. Women of childbearing potential (WOCBP): Refusal or inability to use effective means of contraception (Pearl-Index <1)
14. History of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
15. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
16. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator
17. Known hypersensitivity reaction to any of the components of study treatment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Nivolumab; Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.	Drug: Nivolumab; Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
Experimental: Nivolumab plus Relatlimab; Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit	Drug: Nivolumab plus Relatlimab; Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment	up to 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)		up to 5 years
Disease Control Rate (DCR)	Disease Control Rate (DCR) using Response Criteria in Solid Tumors version 1.1 (RECIST1.1) per site assessment	up to 5 years
Duration of Response (DOR) in patients who achieve partial response (PR) or better		up to 5 years
Progression Free Survival (PFS)		up to 5 years
ORR and DCR for patients with PD-L1-positive tumor expression and/or positive LAG-3 expression of tumor-infiltrating cells		up to 5 years
Number and severity of adverse events		up to 5 years
DOR, PFS and OS for patients with PD-L1-positive tumor expression and/or positive LAG-3 expression of tumor-infiltrating cells		up to 5 years

Collaborators and Investigators

• Sponsor: Salzburger Landeskliniken
• Collaborators: Bristol-Myers Squibb
• Investigators: Principal Investigator: Martin Laimer, MD, Salzburger Landeskliniken

Study record dates

Study Major Dates

• Study Start (Actual): March 6, 2017
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: December 17, 2019
• First Submitted That Met QC Criteria: December 17, 2019
• First Posted (Actual): December 19, 2019

Study Record Updates

• Last Update Posted (Actual): April 18, 2024
• Last Update Submitted That Met QC Criteria: April 17, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Nivolumab; Relatlimab
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Neoplasms, Squamous Cell; Carcinoma; Carcinoma, Squamous Cell; Skin Neoplasms; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors; Nivolumab; Relatlimab
• Other Study ID Numbers: CA209-587

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes